Clinical Trials for Non-Small Cell Lung Cancer

IIT2021-12-Reckamp-Osi105: Phase I Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates the combination of osimertinib and carotuximab, a monoclonal antibody targeting endoglin to disrupt angiogenesis, in patients with stage IV or recurrent/metastatic non-squamous NSCLC with specific EGFR mutations who have progressed after prior EGFR TKI therapies.

ClinicalTrials.gov ID: NCT05401110

A Phase I Open-Label, Dose Escalation Study of the Safety and Tolerability of ANK-101 in Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adults with advanced solid tumors who have progressed after standard treatments, testing ANK-101, an investigational immunotherapy that selectively activates IL-12 within tumors to enhance local anti-tumor immunity through intratumoral injections while limiting systemic exposure.

ClinicalTrials.gov ID: NCT06171750

A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates BMS-986463 in patients with advanced malignant solid tumors, specifically targeting non-small cell lung cancer, high-grade serous ovarian carcinoma, and uterine serous carcinoma, in patients with an ECOG performance status of 0 or 1. The study includes dose escalation and expansion arms and requires patients to have at least one biopsy-suitable lesion, excluding those with leptomeningeal metastases or certain concurrent malignancies.

ClinicalTrials.gov ID: NCT06476808

An Open-label, Phase 1 Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SMP-3124LP in Adults With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adults with advanced solid tumors, including specific cancers like platinum-resistant ovarian and triple-negative breast cancer, using SMP-3124LP, a CHK1 inhibitor targeting the DNA damage response to induce cancer cell apoptosis.

ClinicalTrials.gov ID: NCT06526819

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination with Tislelizumab, in Participants with Selected Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates the safety and antitumor activity of BGB-B2033, a bispecific antibody targeting GPC3 and 4-1BB, alone or with the PD-1 inhibitor tislelizumab, in adults with advanced or metastatic tumors, including hepatocellular carcinoma and GPC3-positive lung cancer. Participants must have unresectable, measurable lesions and meet specific health criteria.

ClinicalTrials.gov ID: NCT06427941

A First-In-Human (FIH) Phase I/II Open-label, Multicentre, Dose Escalation and Expansion Trial of VERT-002 in Patients with Locally Advanced or Metastatic Solid Tumors Including Non-small Cell Lung Cancer (NSCLC) Harboring Mesenchymal-Epithelial Transition (MET) Alterations

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adult patients with relapsed or refractory locally advanced or metastatic solid tumors, including non-small cell lung cancer with MET alterations, who receive VERT-002, a monoclonal antibody targeting c-MET for tumor degradation, after exhausting standard treatments.

ClinicalTrials.gov ID: NCT06669117

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1310 in Subjects With Advanced/Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial targets adult patients with advanced or metastatic solid tumors who have exhausted standard treatments, focusing on the HER3-targeting antibody-drug conjugate DB-1310, administered alone or with trastuzumab or osimertinib, to assess safety and preliminary efficacy.

ClinicalTrials.gov ID: NCT05785741

Administration of T Cells Expressing a 2nd Generation GD2 Chimeric Antigen Receptor, IL-15, and iCaspase9 Safety Switch in Subjects With Lung Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates the safety and dosing of iC9-GD2.CAR.IL-15 T cell therapy, which targets the GD2 antigen and includes IL-15 and a safety switch, in adult patients with extensive stage lung cancer or stage IV non-small cell lung cancer unresponsive to platinum-based and PD-1/PD-L1 inhibitor treatments.

ClinicalTrials.gov ID: NCT05620342

A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates the safety and tolerability of MGC026, an investigational drug administered via IV infusion, in adults with unresectable, locally advanced, or metastatic solid tumors, including squamous cell cancer, lung cancer, and hepatocellular cancer, focusing on those with relapsed or refractory conditions.

ClinicalTrials.gov ID: NCT06242470

A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B694, an Autologous Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with recurrent unresectable, locally advanced, or metastatic solid tumors expressing Mesothelin (MSLN) and with lost HLA-A*02 expression, such as colorectal, non-small cell lung, ovarian cancer, and mesothelioma, to evaluate A2B694, an autologous logic-gated Tmod CAR T-cell therapy targeting MSLN-positive and HLA-A*02-negative cancer cells. Patients receive preconditioning lymphodepletion before the A2B694 infusion.

ClinicalTrials.gov ID: NCT06051695